The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.
Ignace Vergote
No relevant relationships to disclose
Douglas Wilmot Ball
Research Funding - Eisai
Masatoshi Kudo
Research Funding - Bayer; Daiichi Sankyo; Eisai
Pallavi Sachdev
Employment or Leadership Position - Eisai
Mark Matijevic
Employment or Leadership Position - Eisai
Tadashi Kadowaki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Yasuhiro Funahashi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai (I); Eisai
Keith Flaherty
Consultant or Advisory Role - Eisai